MedTrace Logo

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

NCT05426811 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-06-29

No results posted yet for this study

Summary

This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.

Conditions

  • Regorafenib
  • Raltitrexed
  • Colorectal Neoplasms
  • Third-line Treatment

Interventions

DRUG

Regorafenib

Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks

DRUG

Raltitrexed

Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks

Sponsors & Collaborators

  • The People's Hospital of Liaoning Province

    collaborator OTHER

  • Anshan Tumor Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Benxi Cental Hospital

    collaborator OTHER

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, PhD · First Hospital of China Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-07-01
Completion
2025-12-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05426811 on ClinicalTrials.gov